Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,977 | 464 | 3,467 |
| Samples | 1,233 | 209 | 1,010 |
| Peptides | 920 | 145 | 806 |
Function
NOS1 · Nitric oxide synthase 1
The protein encoded by this gene belongs to the family of nitric oxide synthases, which synthesize nitric oxide from L-arginine. Nitric oxide is a reactive free radical, which acts as a biologic mediator in several processes, including neurotransmission, and antimicrobial and antitumoral activities. In the brain and peripheral nervous system, nitric oxide displays many properties of a neurotransmitter, and has been implicated in neurotoxicity associated with stroke and neurodegenerative diseases, neural regulation of smooth muscle, including peristalsis, and penile erection. This protein is ubiquitously expressed, with high level of expression in skeletal muscle. Multiple transcript variants that differ in the 5' UTR have been described for this gene but the full-length nature of these transcripts is not known. Additionally, alternatively spliced transcript variants encoding different isoforms (some testis-specific) have been found for this gene.[provided by RefSeq, Feb 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 860 amino-acid changes on canonical ENST00000317775 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NOS1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NOS1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Melanoma | 24/210 11% | 221/1899 12% |
| Endometrial Carcinoma | 12/42 29% | 34/612 6% |
| Other Solid Cancers | 9/94 10% | 82/1515 5% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 32/304 11% | 57/1390 4% |
| Squamous Cell Lung Carcinoma | 10/57 18% | 35/810 4% |
| Colorectal Carcinoma | 30/143 21% | 137/3239 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Gastric Carcinoma | 5/74 7% | 61/1809 3% |
| Neuroendocrine Tumour | 13/154 8% | 10/577 2% |
| Small Cell Lung Carcinoma | 1/9 11% | 22/752 3% |
| Bladder Carcinoma | 3/58 5% | 25/956 3% |
| Adrenocortical Carcinoma | 2/3 67% | 1/112 1% |
| Other Sarcomas | 4/69 6% | 14/699 2% |
| Cervical Carcinoma | 3/35 9% | 7/422 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Mesothelioma | 2/62 3% | 2/165 1% |
| Plasma Cell Myeloma | 2/44 5% | 4/305 1% |
| Hepatocellular Carcinoma | 0/46 0% | 36/2210 2% |
| Kidney Carcinoma | 1/85 1% | 30/1862 2% |
| Head and Neck Carcinoma | 5/85 6% | 20/1574 1% |
| Glioma | 0/52 0% | 30/2127 1% |
| Pancreatic Carcinoma | 5/89 6% | 16/1611 1% |
| Biliary Tract Carcinoma | 0/54 0% | 12/950 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 30/2550 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
Mutation Distribution
Where NOS1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NOS1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,977 mutations in NOS1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|